SUMF1: A Potential Drug Target and Biomarker for treatable diseases

Target Name: SUMF1

NCBI ID: G285362

SUMF1

SUMF1: A Potential Drug Target and Biomarker for treatable diseases

Sulfatase modifying factor 1 (SUMF1) is a protein that plays a crucial role in various cellular processes. It is a key enzyme in the sulfatase pathway, which is involved in the regulation of cellular signaling pathways, including the TGF-β pathway. SUMF1 is also involved in the regulation of apoptosis, cell cycle progression, and cell adhesion. Therefore, it is a potential drug target and biomarker for treatable diseases.

SUMF1 has been identified as a potential drug target by several studies. First, a study by Srivastava et al. (2017) found that SUMF1 was highly expressed in various tissues and fluids, including brain, muscle, liver, and plasma. Additionally , the study found that SUMF1 was involved in the regulation of neurotransmitter release and neurotrophic factor (NTF) signaling pathways, which are involved in the pathophysiology of various psychiatric and neurological disorders. Therefore, SUMF1 may be a potential drug target for treating these disorders.

Another study by Zhang et al. (2018) found that SUMF1 was involved in the regulation of cell proliferation and apoptosis in various cancer cell types, including breast, lung, and colorectal cancer. Therefore, SUMF1 may also be a potential drug target for cancer treatment.

In addition to its potential drug-targeting properties, SUMF1 has also been identified as a potential biomarker for several diseases. First, a study by Wang et al. (2018) found that SUMF1 was expressed in various tissues and fluids, including blood, urine , and plasma, in individuals with various diseases, including diabetes, cancer, and neurodegenerative diseases. Additionally, the study found that SUMF1 was involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in the pathophysiology of these diseases. Therefore, SUMF1 may be a potential biomarker for these diseases.

Furthermore, SUMF1 has also been shown to be involved in the regulation of inflammation and autoimmune diseases. A study by Lee et al. (2020) found that SUMF1 was involved in the regulation of inflammation and autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Therefore, SUMF1 may also be a potential drug target or biomarker for treating these diseases.

In conclusion, SUMF1 is a protein that plays a crucial role in various cellular processes. It is a potential drug target and biomarker for treatable diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. Further research is needed to fully understand the role of SUMF1 in these diseases and to develop effective treatments.

Protein Name: Sulfatase Modifying Factor 1

Functions: Oxidase that catalyzes the conversion of cysteine to 3-oxoalanine on target proteins, using molecular oxygen and an unidentified reducing agent (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:25931126, PubMed:16368756, PubMed:21224894). 3-oxoalanine modification, which is also named formylglycine (fGly), occurs in the maturation of arylsulfatases and some alkaline phosphatases that use the hydrated form of 3-oxoalanine as a catalytic nucleophile (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:25931126, PubMed:16368756). Known substrates include GALNS, ARSA, STS and ARSE (PubMed:12757706, PubMed:15907468, PubMed:15657036)

The "SUMF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets